Two additional prospective trials of combination VEGFR TKI and ICI in unresectable or metastatic ACC are underway: a second trial of cabozantinib and atezolizumab and a trial of lenvatinib and pembrolizumab (Table 2).48,49. This evidence concerns the gene KDR and adrenal cortex carcinoma.